The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015
Open accessAbstract
IMPORTANCE Liver cancer is among the leading causes of cancer deaths globally.The most common causes for liver cancer include hepatitis B virus (HBV) and hepatitis C virus (HCV) infection and alcohol use.OBJECTIVE To report results of the Global Burden of Disease (GBD) 2015 study on primary liver cancer incidence, mortality, and disability-adjusted life-years (DALYs) for 195 countries or territories from 1990 to 2015, and present global, regional, and national estimates on the burden of liver cancer attributable to HBV, HCV, alcohol, and an "other" group that encompasses residual causes. DESIGN, SETTINGS, AND PARTICIPANTSMortality was estimated using vital registration and cancer registry data in an ensemble modeling approach.Single-cause mortality estimates were adjusted for all-cause mortality.Incidence was derived from mortality estimates and the mortality-to-incidence ratio.Through a systematic literature review, data on the proportions of liver cancer due to HBV, HCV, alcohol, and other causes were identified.Years of life lost were calculated by multiplying each death by a standard life expectancy.Prevalence was estimated using mortality-to-incidence ratio as surrogate for survival.Total prevalence was divided into 4 sequelae that were multiplied by disability weights to derive years lived with disability (YLDs).DALYs were the sum of years of life lost and YLDs. MAIN OUTCOMES AND MEASURESLiver cancer mortality, incidence, YLDs, years of life lost, DALYs by etiology, age, sex, country, and year. RESULTSThere were 854 000 incident cases of liver cancer and 810 000 deaths globally in 2015, contributing to 20 578 000 DALYs.Cases of incident liver cancer increased by 75% between 1990 and 2015, of which 47% can be explained by changing population age structures, 35% by population growth, and -8% to changing age-specific incidence rates.The male-to-female ratio for age-standardized liver cancer mortality was 2.8.Globally, HBV accounted for 265 000 liver cancer deaths (33%), alcohol for 245 000 (30%), HCV for 167 000 (21%), and other causes for 133 000 (16%) deaths, with substantial variation between countries in the underlying etiologies. CONCLUSIONS AND RELEVANCELiver cancer is among the leading causes of cancer deaths in many countries.Causes of liver cancer differ widely among populations.Our results show that most cases of liver cancer can be prevented through vaccination, antiviral treatment, safe blood transfusion and injection practices, as well as interventions to reduce excessive alcohol use.In line with the Sustainable Development Goals, the identification and elimination of risk factors for liver cancer will be required to achieve a sustained reduction in liver cancer burden.The GBD study can be used to guide these prevention efforts.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
The National Comprehensive Cancer Network: Present and future directions
McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+<2057::aid-cncr14>3.0.co;2-a · Cited by 16,766
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Correspondence - Tranexamic acid for traumatic brain injury
(2005) · London School of Economics and Political Science Theses Online (London School of Economics and Political Science) · doi:10.1016/s0140-6736 · Cited by 11,894
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
International Agency for Research on Cancer
National Cancer Institute (2020) · Definitions · doi:10.32388/pfg7jq · Cited by 9,435
Vos, T., Allen, C., Arora, M., Barber, R. M., Bhutta, Z. A., Brown, A., Carter, A., Casey, D. C., Charlson, F. J., Chen, A. Z., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31678-6 · Cited by 7,253
Self-citationWang, H., Naghavi, M., Allen, C., Barber, R. M., Bhutta, Z. A., Carter, A., Casey, D. C., Charlson, F. J., Chen, A. Z., Coates, M. M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31012-1 · Cited by 6,596
Self-citationGlobal Burden of Disease Cancer Collaboration, Fitzmaurice, C., Allen, C., Barber, R. M., Barregard, L., Bhutta, Z. A., Brenner, H., Dicker, D. J., Chimed-Orchir, O., Dandona, R., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.5688 · Cited by 6,215
Self-citationA New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,936
Cited by
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Llovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., & Finn, R. S. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00240-3 · Cited by 7,055
Global Burden of Disease Cancer Collaboration, Fitzmaurice, C., Allen, C., Barber, R. M., Barregard, L., Bhutta, Z. A., Brenner, H., Dicker, D. J., Chimed-Orchir, O., Dandona, R., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.5688 · Cited by 6,215
Self-citationCao, W., Chen, H.-D., Yu, Y.-W., Li, N., & Chen, W.-Q. (2021) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001474 · Cited by 2,865
Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention
Huang, D. Q., El-Serag, H. B., & Loomba, R. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00381-6 · Cited by 1,855
Global Burden of Disease Cancer Collaboration, Fitzmaurice, C., Akinyemiju, T. F., Al Lami, F. H., Alam, T., Alizadeh-Navaei, R., Allen, C., Alsharif, U., Alvis-Guzman, N., Amini, E., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.2706 · Cited by 1,518
Self-citationSeitz, H. K., Bataller, R., Cortez-Pinto, H., Gao, B., Gual, A., Lackner, C., Mathurin, P., Mueller, S., Szabo, G., & Tsukamoto, H. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0014-7 · Cited by 1,271
Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis
Moon, A. M., Singal, A. G., & Tapper, E. B. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.07.060 · Cited by 1,150
Epidemiology and surveillance for hepatocellular carcinoma: New trends
Singal, A. G., Lampertico, P., & Nahon, P. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.08.025 · Cited by 1,102
Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Benson, A. B., D’Angelica, M. I., Abbott, D. E., Anaya, D. A., Anders, R., Are, C., Bachini, M., Borad, M., Brown, D., Burgoyne, A., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0022 · Cited by 1,003
Liu, Z., Jiang, Y., Yuan, H., Fang, Q., Cai, N., Suo, C., Jin, L., Zhang, T., & Chen, X. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.12.001 · Cited by 823
Paik, J. M., Golabi, P., Younossi, Y., Mishra, A., & Younossi, Z. M. (2020) · Hepatology · doi:10.1002/hep.31173 · Cited by 788
Evolving therapeutic landscape of advanced hepatocellular carcinoma
Yang, C., Zhang, H., Zhang, L., Zhu, A. X., Bernards, R., Qin, W., & Wang, C. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00704-9 · Cited by 727
The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis
Stockdale, A. J., Kreuels, B., Henrion, M. Y. R., Giorgi, E., Kyomuhangi, I., de Martel, C., Hutin, Y., & Geretti, A. M. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.04.008 · Cited by 688
The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma
Donne, R., & Lujambio, A. (2023) · Hepatology · doi:10.1002/hep.32740 · Cited by 631
International trends in hepatocellular carcinoma incidence, 1978–2012
Petrick, J. L., Florio, A. A., Znaor, A., Ruggieri, D., Laversanne, M., Alvarez, C. S., Ferlay, J., Valery, P. C., Bray, F., & McGlynn, K. A. (2020) · International Journal of Cancer · doi:10.1002/ijc.32723 · Cited by 594
Global Epidemiology and Genetics of Hepatocellular Carcinoma
Toh, M. R., Wong, E. Y. T., Wong, S. H., Ng, A. W. T., Loo, L.-H., Chow, P. K.-H., & Ngeow, J. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.01.033 · Cited by 583
Brief introduction of medical database and data mining technology in big data era
Yang, J., Li, Y., Liu, Q., Li, L., Feng, A., Wang, T., Zheng, S., Xu, A., & Lyu, J. (2020) · Journal of Evidence-Based Medicine · doi:10.1111/jebm.12373 · Cited by 574
Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline
Gordan, J. D., Kennedy, E. B., Abou-Alfa, G. K., Beg, M. S., Brower, S. T., Gade, T. P., Goff, L., Gupta, S., Guy, J., Harris, W. P., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.02672 · Cited by 570
Peiseler, M., Schwabe, R., Hampe, J., Kubes, P., Heikenwälder, M., & Tacke, F. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.06.012 · Cited by 564
Global epidemiology of alcohol-associated cirrhosis and HCC: trends, projections and risk factors
Huang, D. Q., Mathurin, P., Cortez-Pinto, H., & Loomba, R. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00688-6 · Cited by 553
Huang, D. Q., Singal, A. G., Kono, Y., Tan, D. J. H., El-Serag, H. B., & Loomba, R. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.05.003 · Cited by 534
Qi, J., Li, M., Wang, L., Hu, Y., Liu, W., Long, Z., Zhou, Z., Yin, P., & Zhou, M. (2023) · The Lancet Public Health · doi:10.1016/s2468-2667(23)00211-6 · Cited by 530
Biomarkers in Hepatocellular Carcinoma: Diagnosis, Prognosis and Treatment Response Assessment
Piñero, F., Dirchwolf, M., & Pessôa, M. G. (2020) · Cells · doi:10.3390/cells9061370 · Cited by 498
Surveillance for Hepatocellular Carcinoma: Current Best Practice and Future Direction
Kanwal, F., & Singal, A. G. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.02.049 · Cited by 471
Behary, J., Amorim, N., Jiang, X.-T., Raposo, A., Gong, L., McGovern, E., Ibrahim, R., Chu, F., Stephens, C., Jebeili, H., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20422-7 · Cited by 470
Hepatocellular carcinoma: molecular mechanism, targeted therapy, and biomarkers
Wang, Y., & Deng, B. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10084-4 · Cited by 415
Shigeta, K., Datta, M., Hato, T., Kitahara, S., Chen, I. X., Matsui, A., Kikuchi, H., Mamessier, E., Aoki, S., Ramjiawan, R. R., et al. (2020) · Hepatology · doi:10.1002/hep.30889 · Cited by 409
Hepatocellular carcinoma in the setting of alcohol-related liver disease
Ganne-Carrié, N., & Nahon, P. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.10.008 · Cited by 360
Liver cancer incidence and mortality in China: Temporal trends and projections to 2030
Zheng, R., Office for Cancer Registry, N. C. C. C. R. C. F. C. H., Qu, C., Zhang, S., Zeng, H., Sun, K., Gu, X., Xia, C., Yang, Z., Li, H., et al. (2018) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2018.06.01 · Cited by 343
Mazzaferro, V., Citterio, D., Bhoori, S., Bongini, M., Miceli, R., De Carlis, L., Colledan, M., Salizzoni, M., Romagnoli, R., Antonelli, B., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30224-2 · Cited by 341
Disease Burden of Hepatocellular Carcinoma: A Global Perspective
Sayiner, M., Golabi, P., & Younossi, Z. M. (2019) · Digestive Diseases and Sciences · doi:10.1007/s10620-019-05537-2 · Cited by 339
Ahn, J. C., Teng, P., Chen, P., Posadas, E., Tseng, H., Lu, S. C., & Yang, J. D. (2021) · Hepatology · doi:10.1002/hep.31165 · Cited by 338
Hu, Z., Chen, G., Zhao, Y., Gao, H., Li, L., Yin, Y., Jiang, J., Wang, L., Mang, Y., Gao, Y., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01759-1 · Cited by 327
Gu, B., Shang, X., Yan, M., Li, X., Wang, W., Wang, Q., & Zhang, C. (2021) · Gynecologic Oncology · doi:10.1016/j.ygyno.2021.01.036 · Cited by 326
Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update
Gordan, J. D., Kennedy, E. B., Abou-Alfa, G. K., Beal, E., Finn, R. S., Gade, T. P., Goff, L., Gupta, S., Guy, J., Hoang, H. T., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02745 · Cited by 312
Lipid alterations in chronic liver disease and liver cancer
Paul, B., Lewinska, M., & Andersen, J. B. (2022) · JHEP Reports · doi:10.1016/j.jhepr.2022.100479 · Cited by 308
Hepatocellular carcinoma: old friends and new tricks
Kim, E., & Viatour, P. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-00527-1 · Cited by 307
Hepatocellular Carcinoma (HCC) in Egypt: A comprehensive overview
Rashed, W. M., Kandeil, M. A. M., Mahmoud, M. O., & Ezzat, S. (2020) · Journal of the Egyptian National Cancer Institute · doi:10.1186/s43046-020-0016-x · Cited by 283
Wang, S., Zheng, R., Li, J., Zeng, H., Li, L., Chen, R., Sun, K., Han, B., Bray, F., Wei, W., et al. (2024) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(23)00366-7 · Cited by 282
Targeting the PI3K/Akt/mTOR Pathway in Hepatocellular Carcinoma
Sun, E. J., Wankell, M., Palamuthusingam, P., McFarlane, C., & Hebbard, L. (2021) · Biomedicines · doi:10.3390/biomedicines9111639 · Cited by 281
Lyu, N., Kong, Y., Mu, L., Lin, Y., Li, J., Liu, Y., Zhang, Z., Zheng, L., Deng, H., Li, S., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.02.008 · Cited by 281
Updated epidemiology of gastrointestinal cancers in East Asia
Huang, J., Lucero-Prisno, D. E., Zhang, L., Xu, W., Wong, S. H., Ng, S. C., & Wong, M. C. S. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00726-3 · Cited by 269
Guidelines Insights: Hepatobiliary Cancers, Version 2.2019
Benson, A. B., D’Angelica, M. I., Abbott, D. E., Abrams, T. A., Alberts, S. R., Anaya, D. A., Anders, R., Are, C., Brown, D., Chang, D. T., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0019 · Cited by 269
Huang, L., Sun, H., Sun, L., Shi, K., Chen, Y., Ren, X., Ge, Y., Jiang, D., Liu, X., Knoll, W., et al. (2023) · Nature Communications · doi:10.1038/s41467-022-35696-2 · Cited by 266
Golabi, P., Paik, J. M., AlQahtani, S., Younossi, Y., Tuncer, G., & Younossi, Z. M. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.05.022 · Cited by 259
Hou, P.-P., Luo, L.-J., Chen, H.-Z., Chen, Q.-T., Bian, X.-L., Wu, S.-F., Zhou, J.-X., Zhao, W.-X., Liu, J.-M., Wang, X.-M., et al. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.05.004 · Cited by 253
Harnessing big ‘omics’ data and AI for drug discovery in hepatocellular carcinoma
Chen, B., Garmire, L., Calvisi, D. F., Chua, M.-S., Kelley, R. K., & Chen, X. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0240-9 · Cited by 154
Alcohol-associated liver disease—Global epidemiology
Åberg, F., Jiang, Z. G., Cortez-Pinto, H., & Männistö, V. (2024) · Hepatology · doi:10.1097/hep.0000000000000899 · Cited by 163
Hepatocyte-specific NRF2 activation controls fibrogenesis and carcinogenesis in steatohepatitis
Mohs, A., Otto, T., Schneider, K. M., Peltzer, M., Boekschoten, M., Holland, C. H., Hudert, C. A., Kalveram, L., Wiegand, S., Saez-Rodriguez, J., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2020.09.037 · Cited by 137
Reveron‐Thornton, R. F., Teng, M. L. P., Lee, E. Y., Tran, A., Vajanaphanich, S., Tan, E. X., Nerurkar, S. N., Ng, R. X., Teh, R., Tripathy, D. P., et al. (2022) · Hepatology Communications · doi:10.1002/hep4.1923 · Cited by 97
Ogbo, F. A., Mathsyaraja, S., Koti, R. K., Perz, J., & Page, A. (2018) · BMC Psychiatry · doi:10.1186/s12888-018-1918-1 · Cited by 84
Self-citationLong‐term exposure to air pollution and liver cancer incidence in six European cohorts
So, R., Chen, J., Mehta, A. J., Liu, S., Strak, M., Wolf, K., Hvidtfeldt, U. A., Rodopoulou, S., Stafoggia, M., Klompmaker, J. O., et al. (2021) · International Journal of Cancer · doi:10.1002/ijc.33743 · Cited by 82
Self-citationTsai, P.-C., Kuo, H.-T., Hung, C.-H., Tseng, K.-C., Lai, H.-C., Peng, C.-Y., Wang, J.-H., Chen, J.-J., Lee, P.-L., Chien, R.-N., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2022.09.019 · Cited by 82
Wong, Y. J., Nguyen, V. H., Yang, H.-I., Li, J., Le, M. H., Wu, W.-J., Han, N. X., Fong, K. Y., Chen, E., Wong, C., et al. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2023.0004 · Cited by 77
Roles of Macrophages and Exosomes in Liver Diseases
Shen, M., Shen, Y., Fan, X., Men, R., Ye, T., & Yang, L. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.583691 · Cited by 61
Indian Hedgehog links obesity to development of hepatocellular carcinoma
Chong, Y. C., Lim, T. E., Fu, Y., Shin, E. M., Tergaonkar, V., & Han, W. (2019) · Oncogene · doi:10.1038/s41388-018-0585-5 · Cited by 29
Rusu, I., Pirlog, R., Chiroi, P., Nutu, A., Puia, V. R., Fetti, A. C., Rusu, D. R., Berindan-Neagoe, I., & Al Hajjar, N. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012370 · Cited by 27
Sun, F. S. K., Wong, J. S. L., Mak, L.-Y., Wong, C. C.-L., Chew, V., Li, B. C. W., Leung, R., Cheung, T. T., & Yau, T. (2025) · Liver Cancer · doi:10.1159/000548536 · Cited by 3
Metadata
- Authors
- Global Burden of Disease Liver Cancer Collaboration, Akinyemiju, T., Abera, S., Ahmed, M., Alam, N., Alemayohu, M. A., Allen, C., Al-Raddadi, R., Alvis-Guzman, N., Amoako, Y., Artaman, A., Ayele, T. A., Barac, A., Bensenor, I., Berhane, A., Bhutta, Z., Castillo-Rivas, J., Chitheer, A., Choi, J.-Y., Cowie, B., Dandona, L., Dandona, R., Dey, S., Dicker, D., Phuc, H., Ekwueme, D. U., Zaki, M. E. S., Fischer, F., Fürst, T., Hancock, J., Hay, S. I., Hotez, P., Jee, S. H., Kasaeian, A., Khader, Y., Khang, Y.-H., Kumar, G. A., Kutz, M., Larson, H., Lopez, A., Lunevicius, R., Malekzadeh, R., McAlinden, C., Meier, T., Mendoza, W., Mokdad, A., Moradi-Lakeh, M., Nagel, G., Nguyen, Q., Nguyen, G., Ogbo, F., Patton, G., Pereira, D. M., Pourmalek, F., Qorbani, M., Radfar, A., Roshandel, G., Salomon, J. A., Sanabria, J., Sartorius, B., Satpathy, M., Sawhney, M., Sepanlou, S., Shackelford, K., Shore, H., Sun, J., Mengistu, D. T., Topór-Madry, R., Tran, B., Ukwaja, K. N., Vlassov, V., Vollset, S. E., Vos, T., Wakayo, T., Weiderpass, E., Werdecker, A., Yonemoto, N., Younis, M., Yu, C., Zaidi, Z., Zhu, L., Murray, C. J. L., Naghavi, M., & Fitzmaurice, C.
- Venue
- JAMA Oncology
- Publisher
- American Medical Association (AMA)
- Published
- 2017-12-01
- Volume
- 3
- Issue
- 12
- Pages
- 1683
- ISSN
- 2374-2437 (ISSN-L)
- OpenAlex
- W2761031851
- Cited by
- 1,987
- References
- 41
- FWCI
- 56.12
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.